Ganciclovir (Na) Overview Categories 6 Anti-infective drugs6.5 Antivirals, systemic6.5.1 Herpes and cytomegalovirus infection Page headings Overview Primary Characterstics Indications Pharmacokinetics Contraindications Drug Interactions Side Effects Dosage High Risk Groups Warning / Precautions Storage Conditions Interference in Pathology Brands of Citicoline Manufacturers of Citicoline Primary Characterstics Indications Back to top Pharmacokinetics Back to top Contraindications Back to top Drug Interactions Back to top Side Effects Back to top Dosage Citicoline's dosage details are as follows: Dose Single Dose Frequency Route Instructions Adult Dosage 4.5 mg4.5 (4.5)8 hourlyIntraoccular implantsBy Intraoccular implant release in to viterous cavity at a rate of 1.4 mcg per hour5 to 5 mg/kg5 (5)12 hourlyIVTreatment (For 14-21 days)5 mg/kg5 (5)24 hourlyIVMaintenance (Until adequate recovery of immunity)1 g1 (1)8 hourlyOralFor 5-8 months but its oral absorption is poor Paedriatic Dosage (20kg) Safety not established Neonatal Dosage (3kg) Safety not established High Risk Groups Back to top Warning / Precautions Back to top Storage Conditions Back to top Interference in Pathology Back to top Brands / Trade Names of Lignocaine Back to top Manufacturers of Ganciclovir (Na) in Pakistan Graton Mission Back to top Previous Drug Generic - Next Drug Generic
Ganciclovir (Na) Overview Categories 6 Anti-infective drugs6.5 Antivirals, systemic6.5.1 Herpes and cytomegalovirus infection Page headings Overview Primary Characterstics Indications Pharmacokinetics Contraindications Drug Interactions Side Effects Dosage High Risk Groups Warning / Precautions Storage Conditions Interference in Pathology Brands of Citicoline Manufacturers of Citicoline Primary Characterstics Indications Back to top Pharmacokinetics Back to top Contraindications Back to top Drug Interactions Back to top Side Effects Back to top Dosage Citicoline's dosage details are as follows: Dose Single Dose Frequency Route Instructions Adult Dosage 4.5 mg4.5 (4.5)8 hourlyIntraoccular implantsBy Intraoccular implant release in to viterous cavity at a rate of 1.4 mcg per hour5 to 5 mg/kg5 (5)12 hourlyIVTreatment (For 14-21 days)5 mg/kg5 (5)24 hourlyIVMaintenance (Until adequate recovery of immunity)1 g1 (1)8 hourlyOralFor 5-8 months but its oral absorption is poor Paedriatic Dosage (20kg) Safety not established Neonatal Dosage (3kg) Safety not established High Risk Groups Back to top Warning / Precautions Back to top Storage Conditions Back to top Interference in Pathology Back to top Brands / Trade Names of Lignocaine Back to top Manufacturers of Ganciclovir (Na) in Pakistan Graton Mission Back to top Previous Drug Generic - Next Drug Generic